In a study of more than 800 asymptomatic patients in the US and Canada, researchers at the University of Minnesota found that hydroxychloroquine did not protect them better from Covid-19 than placebo after 4 days of either high and moderate risk of exposure.
Health care workers accounted for 66.4% of the participants in this study, with 62.8% of them being physicians and 23.5% nurses.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The study, which was published in the New England Journal of Medicine, found that 107 of the 821 participants developed Covid-19 in the 14 of follow-up; this was split evenly between the hydroxychloroquine and placebo groups.
“This randomized trial did not demonstrate a significant benefit of hydroxychloroquine as postexposure prophylaxis for Covid-19,” the researchers concluded. “Whether preexposure prophylaxis would be effective in high-risk populations is a separate question, with trials ongoing.”
Last week, the UK’s healthcare regulator paused the University of Oxford’s international CopCov study of hydroxychloroquine and chloroquine to prevent Covid-19 in healthcare workers. This was linked to concerns about the efficacy and safety of the drug based on results of studies in the Lancet.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
